Role of bromodomain and extraterminal (BET) proteins in prostate cancer. (4th March 2023)

• Record Type: Journal Article
• Authors: Mandl, Adel; Markowski, Mark C.; Carducci, Michael A.; Antonarakis, Emmanuel S.
• Is Part Of: Expert opinion on investigational drugs. Volume 32:Number 3(2023)
• Page Start: 213
• Page End: 228
• Publication Date: 2023-03-04
• Subjects: Bromodomain and extraterminal domain inhibitors -- BET -- BRD4 -- prostate cancer -- castration-resistant prostate cancer -- androgen receptor -- clinical trials -- epigenetics; Drugs -- Design -- Periodicals; Drugs, Investigational -- Bibliography; Drugs, Investigational -- Periodicals; 615.1
• DOI: 10.1080/13543784.2023.2186851
• Languages: English
• ISSNs: 1354-3784

Abstract

ABSTRACT: Introduction: The bromodomain and extraterminal (BET) family of proteins are epigenetic readers of acetylated histones and are critical activators of oncogenic networks across many cancers. Therapeutic targeting of BET proteins has been an attractive area of clinical development for metastatic castration-resistant prostate cancer. In recent years, many structurally diverse BET inhibitors have been discovered and tested. Preclinical studies have demonstrated significant antiproliferative activity of BET inhibitors against prostate cancer. However, their clinical success as monotherapies has been limited by treatment-associated toxicities, primary and acquired drug resistance, and a lack of predictive biomarkers of benefit. Areas covered: This review provides an overview of advancements in BET inhibitor design, preclinical research, and conclusions from clinical trials in prostate cancer. We speculate on incorporating BET inhibitors into combination regimens with other agents to improve the therapeutic index of BET inhibition in treating prostate cancer. Expert opinion: The therapeutic potential of BET inhibitors for prostate cancer has been demonstrated in preclinical studies. However, further research is needed to identify biomarkers that can predict sensitivity to BET inhibitors and to develop novel, highly selective inhibitors to reduce toxicities. Finally, BET inhibitors are likely to hold the most clinical potential in combination with other agents.